You are here

Article Text

Article menu
Download PDFPDF
PostScript
Correspondence
The good the bad and the ugly
  1. Paul A Corris1,2,
  2. Sasiharan Sithamparanathan3,
  3. Logan Thirugnanasothy3
  1. 1 National Pulmonary Hypertension Service (Newcastle), Institute of Cellular Medicine, Newcastle upon Tyne, UK
  2. 2 Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
  3. 3 Department of Respiratory Medicine, Freeman Hospital, High Heaton, Newcastle Upon Tyne, UK
  1. Correspondence to Professor Paul A Corris, National Pulmonary Hypertension Service (Newcastle), Institute of Cellular Medicine, 4th Floor William Leech Building, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK; paul.corris{at}newcastle.ac.uk

https://doi.org/10.1136/thoraxjnl-2014-205337

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We were, of course, very interested to read the manuscript by Saggar et al,1 and the accompanying editorial by Nathan2 relating to the use of parenteral treprostinil therapy in patients referred for lung transplantation with pulmonary hypertension (PH) in association with pulmonary fibrosis (PF).

    It is good that there is continued interest in finding a clinical phenotype of patient with PF who may benefit on both symptomatic and prognostic grounds from targeted PH therapy. It is also good because there is a great clinical need to help this group of desperate …

    View Full Text

    Footnotes

    • Contributors PAC conceived the idea and drafted the first version. SS and LT made statistical contribution and amendments to the letter. All authors approved the final version.

    • Competing interests PAC has received support from GSK, Bayer and Actelion for advisory boards and educational meetings. The Newcastle Pulmonary Vascular Service has received grant support from Bayer.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles